{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"OVID","limit":50},"count":50,"signals":[{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"re relevant information and experiences. We conduct patient community outreach and activities to inform our clinical design, educate patients about trial opportunities and support efficient study enrollment. Fit-for-purpose infrastructure We have built a highly specialized, efficient, and focused infrastructure that supports our chosen areas of neurotherapeutics development. This infrastructure spans","filed_date":"2026-03-18","accession":"0001628280-26-019438","full_text":"https://origin.rootz.global/static/filing/0001628280-26-019438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":64,"context":"third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursemen","filed_date":"2026-03-18","accession":"0001628280-26-019438","full_text":"https://origin.rootz.global/static/filing/0001628280-26-019438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"Section 5.9. Intellectual Property has the meaning set forth in Section 3.12. Investor and Investors have the meanings set forth in the recitals. IT Systems has the meaning set forth in Section 3.30. Material Adverse Effect means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, (a) was, is, or would reasonably be expected to be, materially adverse to t","filed_date":"2026-03-18","accession":"0001628280-26-019045","full_text":"https://origin.rootz.global/static/filing/0001628280-26-019045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors.Research and development activities are and will continue to be central to our business model. We expect our research","filed_date":"2025-11-12","accession":"0001636651-25-000012","full_text":"https://origin.rootz.global/static/filing/0001636651-25-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"her risks and uncertainties associated with public health crises and global geopolitical tensions, like tensions between China and Taiwan and the ongoing wars involving Ukraine and Israel, may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting fluctuations in inflation rates may materially affect our business and corresponding financial position","filed_date":"2025-11-12","accession":"0001636651-25-000012","full_text":"https://origin.rootz.global/static/filing/0001636651-25-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors.Research and development activities are and will continue to be central to our business model. We expect our research","filed_date":"2025-08-13","accession":"0001628280-25-040008","full_text":"https://origin.rootz.global/static/filing/0001628280-25-040008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"her risks and uncertainties associated with public health crises and global geopolitical tensions, like tensions between China and Taiwan and the ongoing wars involving Ukraine and Israel, may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting fluctuations in inflation rates may materially affect our business and corresponding financial position","filed_date":"2025-08-13","accession":"0001628280-25-040008","full_text":"https://origin.rootz.global/static/filing/0001628280-25-040008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":74,"context":"this Notice:(1)To elect the nominees named in the attached proxy statement as directors, to serve on the Board for a three-year term.(2)To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in this proxy statement.(3)To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.(4)To approve a series","filed_date":"2025-05-22","accession":"0001628280-25-027146","full_text":"https://origin.rootz.global/static/filing/0001628280-25-027146.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"ties associated with public health crises and global geopolitical tensions, like tensions between China and Taiwan, the ongoing war between Russia and Ukraine and the war involving Israel, may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting fluctuations in inflation rates may materially affect our business and corresponding financial position","filed_date":"2025-05-13","accession":"0001628280-25-024913","full_text":"https://origin.rootz.global/static/filing/0001628280-25-024913.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"-five percent of the shares subject to each option award vested on the one-year anniversary of the grant date and the remaining shares subject to such option awards will vest in 36 equal monthly installments thereafter, subject to the executives continuous service to us through each vesting date. Additionally, in connection with our annual grant process, on February 22, 2024, our Compensation Committ","filed_date":"2025-04-30","accession":"0001628280-25-021055","full_text":"https://origin.rootz.global/static/filing/0001628280-25-021055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":60,"context":"wo completed fiscal years, as applicable, regarding compensation awarded to or earned by our Chief Executive Officer and the two other most highly compensated executive officers, or collectively, the named executive officers, during the fiscal years indicated: | | | Name and Principal Position | Year | Salary($) | OptionAwards($)(1)(2) | Stock Awards(1) | Non-EquityIncentivePlanCompensation($)(3) | All OtherCompensation","filed_date":"2025-04-30","accession":"0001628280-25-021055","full_text":"https://origin.rootz.global/static/filing/0001628280-25-021055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ant information and experiences. We conduct patient disease community outreach and activities to inform our clinical design, educate patients about trial opportunities and support efficient study enrollment. Fit-for-purpose infrastructure We have built a highly specialized, efficient, and focused infrastructure that supports our chosen area of neurotherapeutics development. This infrastructure spans","filed_date":"2025-03-11","accession":"0001628280-25-011844","full_text":"https://origin.rootz.global/static/filing/0001628280-25-011844.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":64,"context":"third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursemen","filed_date":"2025-03-11","accession":"0001628280-25-011844","full_text":"https://origin.rootz.global/static/filing/0001628280-25-011844.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"risks and uncertainties associated with bank failures, public health crises and global geopolitical tensions, like the ongoing war between Russia and Ukraine and the war involving Israel, may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting high inflation rates may materially affect our business and corresponding financial position and cash f","filed_date":"2024-11-12","accession":"0001628280-24-046868","full_text":"https://origin.rootz.global/static/filing/0001628280-24-046868.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"d other risks and uncertainties associated with bank failures, public health crises and global geopolitical tensions, like the ongoing war between Russia and Ukraine and the war in Israel, may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting high inflation rates may materially affect our business and corresponding financial position and cash f","filed_date":"2024-08-13","accession":"0001628280-24-036860","full_text":"https://origin.rootz.global/static/filing/0001628280-24-036860.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"d other risks and uncertainties associated with bank failures, public health crises and global geopolitical tensions, like the ongoing war between Russia and Ukraine and the war in Israel, may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting high inflation rates may materially affect our business and corresponding financial position and cash f","filed_date":"2024-05-14","accession":"0001628280-24-023067","full_text":"https://origin.rootz.global/static/filing/0001628280-24-023067.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":73,"context":"his Notice:(1) To elect the nominees named in the attached proxy statement as directors, to serve on the Board for a three-year term.(2) To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in this proxy statement.(3) To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.(4) To conduct any oth","filed_date":"2024-04-24","accession":"0000950170-24-047673","full_text":"https://origin.rootz.global/static/filing/0000950170-24-047673.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":58,"context":"third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursemen","filed_date":"2024-03-08","accession":"0001628280-24-009809","full_text":"https://origin.rootz.global/static/filing/0001628280-24-009809.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"d other risks and uncertainties associated with bank failures, public health crises and global geopolitical tensions, like the ongoing war between Russia and Ukraine and the war in Israel, may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting high inflation rates may materially affect our business and corresponding financial position and cash f","filed_date":"2023-11-03","accession":"0001628280-23-036564","full_text":"https://origin.rootz.global/static/filing/0001628280-23-036564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"wn, the overall disruption of global healthcare systems and other risks and uncertainties associated with bank failures, public health crises and the ongoing war between Russia and Ukraine may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting high inflation rates may materially affect our business and corresponding financial position and cash f","filed_date":"2023-08-04","accession":"0001628280-23-027430","full_text":"https://origin.rootz.global/static/filing/0001628280-23-027430.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"wn, the overall disruption of global healthcare systems and other risks and uncertainties associated with bank failures, public health crises and the ongoing war between Russia and Ukraine may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting high inflation rates may materially affect our business and corresponding financial position and cash f","filed_date":"2023-05-05","accession":"0001628280-23-016013","full_text":"https://origin.rootz.global/static/filing/0001628280-23-016013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":78,"context":"his Notice:(1) To elect the nominees named in the attached proxy statement as directors, to serve on the Board for a three-year term.(2) To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in this proxy statement.(3) To indicate, on an advisory basis, the preferred frequency of the advisory vote on the compensation of our named executive officers.(4) To ratify the select","filed_date":"2023-04-27","accession":"0000950170-23-014914","full_text":"https://origin.rootz.global/static/filing/0000950170-23-014914.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursemen","filed_date":"2023-03-13","accession":"0001628280-23-007648","full_text":"https://origin.rootz.global/static/filing/0001628280-23-007648.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"sease, including vaccination efforts. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability","filed_date":"2022-11-08","accession":"0001628280-22-028772","full_text":"https://origin.rootz.global/static/filing/0001628280-22-028772.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"sease, including vaccination efforts. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability","filed_date":"2022-08-09","accession":"0001628280-22-021759","full_text":"https://origin.rootz.global/static/filing/0001628280-22-021759.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"sease, including vaccination efforts. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability","filed_date":"2022-05-10","accession":"0000950170-22-008739","full_text":"https://origin.rootz.global/static/filing/0000950170-22-008739.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":44,"context":"that the nominees would prove unable to serve if elected. There are no arrangements or understandings between us and any director, or the nominees for directorship, pursuant to which such person was selected as a director or nominee. Proxies cannot be voted for a greater number of persons than the number of nominees named in this proposal. It is our policy to encourage, but not require, directors and nominees for dire","filed_date":"2022-04-29","accession":"0000950170-22-006707","full_text":"https://origin.rootz.global/static/filing/0000950170-22-006707.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ationships with patients, caregivers, families, disease foundations and key opinion leaders, to better understand the history of these disorders, raise awareness, identify patients and facilitate enrollment of clinical trials; &#x2022; identify clinically meaningful endpoints based on input from patients and their physicians and caregivers; and &#x2022; develop digital capabilities to be deeply infor","filed_date":"2022-03-15","accession":"0000950170-22-003668","full_text":"https://origin.rootz.global/static/filing/0000950170-22-003668.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursemen","filed_date":"2022-03-15","accession":"0000950170-22-003668","full_text":"https://origin.rootz.global/static/filing/0000950170-22-003668.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"e impaired. &#xf0b7; Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. &#xf0b7; Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, thi","filed_date":"2021-11-10","accession":"0000950170-21-004066","full_text":"https://origin.rootz.global/static/filing/0000950170-21-004066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"e impaired. &#xf0b7; Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. &#xf0b7; Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, thi","filed_date":"2021-08-16","accession":"0000950170-21-001457","full_text":"https://origin.rootz.global/static/filing/0000950170-21-001457.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"paired. | | |  |  |  Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. | | |  |  |  Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients,","filed_date":"2021-05-13","accession":"0001564590-21-027623","full_text":"https://origin.rootz.global/static/filing/0001564590-21-027623.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":48,"context":"e that the nominee would prove unable to serve if elected. There are no arrangements or understandings between us and any director, or the nominee for directorship, pursuant to which such person was selected as a director or nominee. Our Board is actively searching for independent and qualified candidates to fill the vacancies and if a qualified nominee is found after the mailing of this proxy statement, the Board may","filed_date":"2021-04-30","accession":"0001564590-21-022189","full_text":"https://origin.rootz.global/static/filing/0001564590-21-022189.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ationships with patients, caregivers, families, disease foundations and key opinion leaders, to better understand the history of these disorders, raise awareness, identify patients and facilitate enrollment of clinical trials; | | |  |  |  identify clinically meaningful endpoints based on input from patients and their physicians and caregivers; and | | |  |  |  develop digital capabilities to engage,","filed_date":"2021-03-15","accession":"0001564590-21-013016","full_text":"https://origin.rootz.global/static/filing/0001564590-21-013016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"paired. | | |  |  |  Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. | | |  |  |  Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients,","filed_date":"2021-03-15","accession":"0001564590-21-013016","full_text":"https://origin.rootz.global/static/filing/0001564590-21-013016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"compound and related information and acceptance by Angelini, Angelini will be required to make a payment towards the $60.0 million aggregate tech transfer and regulatory milestone payments. This fulfillment is out of the Company's control, is subject to reversal and was not probable as of September 30, 2020 therefore this variable consideration is constrained and not part of the upfront transaction p","filed_date":"2020-11-13","accession":"0001564590-20-053666","full_text":"https://origin.rootz.global/static/filing/0001564590-20-053666.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"| |  |  &#x2022; |  Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. | | |  |  &#x2022; |  Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians,","filed_date":"2020-11-13","accession":"0001564590-20-053666","full_text":"https://origin.rootz.global/static/filing/0001564590-20-053666.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"5 (soticlestat), in certain territories. Under the Takeda collaboration, the Company is obligated to pay Takeda future payments if and when certain milestones are achieved. Upon the first patient enrollment in the first Phase 3 trial for the first of the initial indications the Company and Takeda are focusing on in the Takeda collaboration, the Company is obligated to issue to Takeda the number of un","filed_date":"2020-08-10","accession":"0001564590-20-038644","full_text":"https://origin.rootz.global/static/filing/0001564590-20-038644.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"lly to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our","filed_date":"2020-08-10","accession":"0001564590-20-038644","full_text":"https://origin.rootz.global/static/filing/0001564590-20-038644.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"5 (soticlestat), in certain territories. Under the Takeda collaboration, the Company is obligated to pay Takeda future payments if and when certain milestones are achieved. Upon the first patient enrollment in the first Phase 3 trial for the first of the initial indications the Company and Takeda are focusing on in the Takeda collaboration, the Company is obligated to issue to Takeda the number of un","filed_date":"2020-05-07","accession":"0001564590-20-023002","full_text":"https://origin.rootz.global/static/filing/0001564590-20-023002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"lly to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our","filed_date":"2020-05-07","accession":"0001564590-20-023002","full_text":"https://origin.rootz.global/static/filing/0001564590-20-023002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":55,"context":"reholdermeeting.com/OVID2020 and entering your control number (included in the Notice Regarding Availability of Proxy Materials mailed to you). |  | |  |  |  | |  Purposes |  (1)To elect the nominees named in the attachedproxy statementas directors,to serve on the Boardfor a three-yearterm. (2)To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December31, 2020. (3)To conduct any","filed_date":"2020-04-24","accession":"0001564590-20-018268","full_text":"https://origin.rootz.global/static/filing/0001564590-20-018268.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"ationships with patients, caregivers, families, disease foundations and key opinion leaders, to better understand the history of these disorders, raise awareness, identify patients and facilitate enrollment of clinical trials; | | |  |  &#x2022; |  identify clinically meaningful endpoints based on input from patients and their physicians and caregivers; and | | |  |  &#x2022; |  develop digital capab","filed_date":"2020-03-11","accession":"0001564590-20-010108","full_text":"https://origin.rootz.global/static/filing/0001564590-20-010108.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Other Healthcare Laws Because of our current and future arrangements with healthcare professionals, principal investigators, consultants,","filed_date":"2020-03-11","accession":"0001564590-20-010108","full_text":"https://origin.rootz.global/static/filing/0001564590-20-010108.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy. 25 Cash Flows  The following table summarizes our cash flows for the periods indicated: |  |  |  Nine Months Ended |  |  |","filed_date":"2019-11-08","accession":"0001564590-19-042028","full_text":"https://origin.rootz.global/static/filing/0001564590-19-042028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy. Cash Flows  The following table summarizes our cash flows for the periods indicated: |  |  |  Six Months Ended |  |  |  Six","filed_date":"2019-08-07","accession":"0001564590-19-030178","full_text":"https://origin.rootz.global/static/filing/0001564590-19-030178.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy. 22 Cash Flows  The following table summarizes our cash flows for the periods indicated: |  |  |  Three Months Ended |  |  |","filed_date":"2019-05-07","accession":"0001564590-19-016562","full_text":"https://origin.rootz.global/static/filing/0001564590-19-016562.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":42,"context":"l time |  | |  |  |  | |  Date |  Friday, June7, 2019 |  | |  |  |  | |  Place |  Ovid Therapeutics Inc., 1460 Broadway, New York, New York 10036 |  | |  |  |  | |  Purpose |  (1)To elect the nominee named in the attachedproxy statementas director,to serve on the Boardfor a three-yearterm. (2)To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December31, 2019. (3)To conduct any o","filed_date":"2019-04-24","accession":"0001564590-19-012763","full_text":"https://origin.rootz.global/static/filing/0001564590-19-012763.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ationships with patients, caregivers, families, disease foundations and key opinion leaders, to better understand the history of these disorders, raise awareness, identify patients and facilitate enrollment of clinical trials; | | |  |  &#x2022; |  identify clinically meaningful endpoints based on input from patients and their physicians and caregivers; and | | |  |  &#x2022; |  develop digital capab","filed_date":"2019-03-07","accession":"0001564590-19-006804","full_text":"https://origin.rootz.global/static/filing/0001564590-19-006804.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OVID","company":"Ovid Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. Other Healthcare Laws Because of our current and future arrangements with healthcare professionals, principal investigators, consultants,","filed_date":"2019-03-07","accession":"0001564590-19-006804","full_text":"https://origin.rootz.global/static/filing/0001564590-19-006804.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"d011d58df26039780fc33e0e47dee11a5e7b0b3e0d03276a8af9b0baf769c14d","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"bb97b5ad6db2fa1c32e62b7f875777bfa9f2169a0e8b9a41a493d6ced33422e4","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":7,"hourly_limit":500,"remaining":493,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}